

AMENDMENTS

Please amend the following claims:

Claim 1 (Currently amended) A pharmaceutical composition comprising:

a) a psychotropic, neurotropic or neurological drug, or an antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drug, wherein the drug is L-dopa, hydroxytryptamine, amantadine, benztropine, bromocryptine, diphenhydramine, levodopa, pergolid, trihexphenidyl, ethosuximide, valproic acid, carbamazepine, 10-hydroxycarbamazepine, 11-hydroxycarbamazepine, primidone, gabapentin, lamotrigine, felbamate, paramethadione, trimethadione, phenothiazine, thioxanthene, clozapine, haldoperidol, loxapine, a benzodiazapene antidepressants of the norepinephrine reuptake inhibitor type, a monoamine oxidase inhibitor, carotene, glutathione, N-acetylcysteine, methotrexate, azidothymidine, dideoxyinosine, dideoxycytosine, acyclovir, or gancyclovir;

b) ~~_____ an amino acid or amino acid derivative specifically transported into a physiologically protected site, wherein the amino acid or derivative thereof is 5-hydroxytryptophan, serotonin, or melatonin; and~~

c) _____ a spacer having two linker functional groups and

d) _____ a spacer,

~~wherein the spacer has a first end and a second end and wherein the amino acid or amino acid derivative is attached to the first end of the spacer through a first linker functional group and the drug is attached to the second end of the spacer through a second linker functional group.~~

Claim 2 (cancelled)

Claim 3 (Currently amended). A pharmaceutical composition according to Claim 1 wherein the spacer allows the drug to act without being released at an intracellular site and wherein the first linker functional group ~~attached to the first end of the spacer~~ is strong and the second linker functional group ~~attached to the second end of the spacer~~ is weak.

Claim 4 (Currently amended). A pharmaceutical composition according to Claim 1 wherein the spacer allows the facilitated hydrolytic release of the drug at an intracellular site and wherein the first linker functional group ~~attached to the first end of the spacer~~ is strong and the second linker functional group ~~attached to the second end of the spacer~~ is weak.

Claim 5 (Currently amended). A pharmaceutical composition according to Claim 1 wherein the spacer allows the facilitated enzymatic release of the drug at an intracellular site and wherein the first linker functional group ~~attached to the first end of the spacer~~ is strong and the second linker functional group ~~attached to the second end of the spacer~~ is weak.

Claim 6 (cancelled)

Claim 7 (Currently amended). A pharmaceutical composition comprising:

a) a psychotropic, neurotropic or neurological drug, or an antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drug, wherein the drug is L-dopa, hydroxytryptamine, amantadine, benztropine, bromocryptine, diphenhydramine, levadopa, pergolid, trihexphenidyl, ethosuximide, valproic acid, carbamazepine, 10-hydroxycarbamazepine, 11-hydroxycarbamazepine, primidone, gabapentin, lamotrigine, felbamate, paramethadione, trimethadione, phenothiazine, thioxantheme, clozapine, haldoperidol, loxapine, a benzodiazapene antidepressants of the norepinephrine reuptake inhibitor type, a monoamine oxidase inhibitor, carotene, glutathione, N-acetylcysteine, methotrexate, azidothymidine, dideoxyinosine, dideoxycytosine, acyclovir, or gancyclovir,

wherein the drug has a first functional linker group, and

b) ~~an amino acid or amino acid derivative specifically transported into a physiologically protected site, wherein the amino acid or derivative thereof is 5-hydroxytryptophan, serotonin, or melatonin,~~

~~wherein the amino acid or derivative thereof has~~ having a second functional linker group,

wherein the drug is covalently linked to ~~the amino acid or amino acid derivative~~
5-hydroxytryptophan, serotonin, or melatonin by a chemical bond between the first and
second functional linker groups.

Claim 8 (Previously presented). A pharmaceutical composition according to
Claim 7 wherein the first functional linker group is a hydroxyl group, a primary or
secondary amino group, a phosphate group or a carboxylic acid group.

Claim 9 (Previously presented). A pharmaceutical composition according to
Claim 7 wherein the second functional linker group is a hydroxyl group, a primary or
secondary amino group, a phosphate group or a carboxylic acid group.

Claims 10-33 (cancelled)